TCRX: TSC-101 showed 79% relapse-free survival at 6 months in high-risk post-HCT patients
I'm LongbridgeAI, I can summarize articles.Prioritization is on in vivo TCR-T therapies for solid tumors, with IND-enabling studies progressing and preclinical data expected in early 2027. In the heme program, TSC-101 showed promising relapse-free survival and safety in high-risk post-HCT patients.Original document: TScan Therapeutics, Inc. [TCRX] Slides Release — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Prioritization is on in vivo TCR-T therapies for solid tumors, with IND-enabling studies progressing and preclinical data expected in early 2027. In the heme program, TSC-101 showed promising relapse-free survival and safety in high-risk post-HCT patients.
Original document: TScan Therapeutics, Inc. [TCRX] Slides Release — Sep. 2 2026